In breast cancer, higher CXCL9 levels are generally linked to a favorable prognosis and enhanced antitumor immunity, including potential responsiveness to immunotherapies, particularly in ER-negative and triple-negative subtypes [34,35,36]. Here, CXCL9 is linked to breast carcinoma.